타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | mirvetuximab soravtansine-gynx (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials | |
|---|---|---|
Overview Program | Elahere (mirvetuximab soravtansine-gynx) | Luveltamab tazevibulin |
Overview Company | AbbVie / ImmunoGen | Sutro Biopharma, Inc. |
Overview Modality | ADC | ANTIBODY |
Overview Target | FRα (folate receptor alpha) | Ovarian Cancer |
Overview Indication | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | Ovarian Cancer; Epithelial Ovarian Cancer |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | DISCONTINUED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. | — |
Positioning Known limitation | FRα downregulation and multidrug-resistance transporter upregulation. | — |
Positioning Development positioning | 2L–4L platinum-resistant | — |
Technology Payload | DM4 (maytansinoid, tubulin inhibitor) | — |
Technology Linker | Cleavable sulfo-SPDB disulfide, DAR ~3.5 | — |
Technology DAR | DAR 3.5 | — |
MoA Mechanism | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. | — |
MoA Biomarker | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. | — |
Toxicology Species | Rat | — |
Toxicology Major finding | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — |
Toxicology CRS | N/A | — |
Clinical Safety signal | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — |
Clinical Selected reported efficacy | ORR 42% | — |
Clinical Reported ORR | 42% vs 16% (chemotherapy; rounded in NCI report) | — |
Clinical Reported PFS | 5.6 months vs 4.0 months (chemotherapy) | — |
Clinical Reported OS | 16.5 months vs 12.8 months (chemotherapy) | — |
Clinical Result source | NCI approval analysis 2024 — MIRASOL (NCT04209855) | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — |
Clinical Trial ref | NCT04209855 | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | mirvetuximab soravtansine-gynx (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials | |
|---|---|---|
Overview Program | Elahere (mirvetuximab soravtansine-gynx) | Luveltamab tazevibulin |
Overview Company | AbbVie / ImmunoGen | Sutro Biopharma, Inc. |
Overview Modality | ADC | ANTIBODY |
Overview Target | FRα (folate receptor alpha) | Ovarian Cancer |
Overview Indication | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | Ovarian Cancer; Epithelial Ovarian Cancer |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | DISCONTINUED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. | — |
Positioning Known limitation | FRα downregulation and multidrug-resistance transporter upregulation. | — |
Positioning Development positioning | 2L–4L platinum-resistant | — |
Technology Payload | DM4 (maytansinoid, tubulin inhibitor) | — |
Technology Linker | Cleavable sulfo-SPDB disulfide, DAR ~3.5 | — |
Technology DAR | DAR 3.5 | — |
MoA Mechanism | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. | — |
MoA Biomarker | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. | — |
Toxicology Species | Rat | — |
Toxicology Major finding | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — |
Toxicology CRS | N/A | — |
Clinical Safety signal | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — |
Clinical Selected reported efficacy | ORR 42% | — |
Clinical Reported ORR | 42% vs 16% (chemotherapy; rounded in NCI report) | — |
Clinical Reported PFS | 5.6 months vs 4.0 months (chemotherapy) | — |
Clinical Reported OS | 16.5 months vs 12.8 months (chemotherapy) | — |
Clinical Result source | NCI approval analysis 2024 — MIRASOL (NCT04209855) | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — |
Clinical Trial ref | NCT04209855 | — |
추천 비교
추천 비교